Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702314 | 1.00 | ALDH1A1 (0.51) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL1754965 | 0.90 | ALDH1A1 (0.55) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL13056588 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL1754963 | 0.85 | PTPN1 (0.47) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL13056589 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL14030155 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL16202235 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL13056593 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL13056590 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL20118123 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123045-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-04-18 | — | — | US | claimed |
| EP-2686438-B1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR | VENTANA MED SYST INC (US) | 2018-04-18 | — | — | EP | claimed |
| US-9562259-B2 | Method of analyzing chromosomal inversions | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-02-07 | — | — | US | claimed |
| EP-2686438-A1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE | Ventana Medical Systems, Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| EP-2539466-A1 | CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES | Ventana Medical Systems, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| EP-2539355-A1 | POLYTAG PROBES | Ventana Medical Systems, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| US-20120301885-A1 | CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES | TANG LEI (US) | 2012-11-29 | — | — | US | claimed |
| US-20120301886-A1 | POLYTAG PROBES | VENTANA MEDICAL SYSTEMS, INC. | 2012-11-29 | — | — | US | claimed |
| US-20120237930-A1 | METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE | VENTANA MEDICAL SYSTEMS, INC. | 2012-09-20 | — | — | US | claimed |
| WO-2012123387-A1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | claimed |
| US-20250223640-A1 | METHODS AND KITS FOR DETECTION OF METHYLATION STATUS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2025-07-10 | — | — | US | disclosed |
| EP-4574995-A2 | METHODS AND KITS FOR DETECTION OF METHYLATION STATUS | Oslo Universitetssykehus HF (NO) | 2025-06-25 | — | — | EP | disclosed |
| EP-3904533-B1 | METHOD FOR DETECTION OF HYDROXYMETHYLATION STATUS | UNIV OSLO HF (NO) | 2025-02-26 | — | — | EP | disclosed |
| US-12126880-B2 | Digitally enhanced microscopy for multiplexed histology | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240123045-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-04-18 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2078197-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | ALDH1A1 2096/4885TP53 3304/4885MAPT 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.